Omeros (OMER) Q1 2026 Earnings Transcript

Omeros reported $11.1 million in Q1 gross YARTEMLEA sales and $9.9 million in net revenue following January FDA approval, with early adoption at 30 accounts and P&T approvals accelerating across top transplant centers. The company also closed a $240 million upfront Novo Nordisk deal, ended the quarter with $135.3 million in cash and investments, and repurchased about 360,000 shares for $4.2 million. Management said YARTEMLEA became cash flow positive in its launch quarter and expects company-wide positive cash flow within 18 months, while CMS J-code and NTAP decisions could further improve reimbursement and uptake.

Analysis

OMER is in the rare biotech transition from binary event risk to operational scaling, and that matters more than the headline launch quarter. The key second-order effect is that reimbursement infrastructure is now de-risking faster than usual: a permanent billing code plus likely inpatient add-on payment should compress the lag between physician intent and hospital procurement, which is where most ultra-rare launches stall. That creates a pull-through effect not just on quarterly sales, but on inventory turns, formulary momentum, and the probability of earlier-line use before patients deteriorate.

The competitive read-through is unfavorable for the complement-inhibition incumbents. If the market starts treating TA-TMA as a “treat early, don’t wait” condition, then the prior standard of waiting for severe progression becomes less defensible, especially when hospitals can be reimbursed more cleanly. That dynamic can shift share away from watchful-waiting behavior and toward OMER’s first-mover advantage, while making a randomized competitor trial look increasingly like a study in a sicker, less comparable population.

The main risk is not demand; it is execution under success. Gross-to-net should widen as 340B penetration increases, and launch economics can get noisy if payer mix, site-of-care mix, or pediatrics skew differently than management expects. The bigger swing factor over the next 1-2 quarters is whether early adoption converts into durable repeat ordering and broader inpatient use before the reimbursement uplift fully hits in Q3/Q4.

Consensus appears to be underappreciating how quickly this can become a cash-generation story rather than a “hopeful launch” story. With a clean balance sheet, buybacks, and a monetized pipeline asset, the stock can rerate on basic SaaS-like launch metrics if order frequency inflects. The contrarian risk is that the market overvalues the one-time novelty of approval and underweights the possibility that YARTEMLEA becomes a standard hospital protocol faster than sell-side models assume.

Key Decisions for Investors

• Long OMER into the J-code effective date and hold through NTAP finalization (1-4 months) — best setup is a positive surprise in repeat ordering and P&T conversions; downside is launch deceleration or gross-to-net drift.
• Buy OMER call spreads 2-3 months out, struck around current spot to +25% — asymmetry favors a rerate if reimbursement catalysts accelerate access; premium risk is capped if adoption stalls.
• Pair trade: long OMER / short AZN over 3-6 months — thesis is that OMER’s first-to-market reimbursement improvements and earlier-treatment pull-through can pressure competitive narrative around the comparator program.
• Add on weakness only if shares fall on noncash accounting noise rather than sales/access data — the real fundamental tell is account reorders, not headline EPS volatility.
• Take profits partially after the August CMS final rule if the stock has already priced in NTAP — that is the most probable catalyst peak before utilization data either validates or disappoints.